Nyxoah SA (NYXH) said Wednesday that Medicare reimbursement for its Genio hypoglossal nerve stimulation therapy will rise sharply in 2026, with Hospital Outpatient Department payments for CPT 64568 set to increase about 48% to roughly $45,000 effective Jan. 1 under the final CMS
Nyxoah’s Genio therapy gets significant 2026 Medicare reimbursement increases under final CMS rule
